Trial reportBritish journal of cancer2008
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Trial report in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06900647 (Phase I Study to Evaluate the Safety and Preliminary Efficacy of Bortezomib Combined With Cisplatin in Patients With Recurrent or Metastatic Breast Cancer), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study to Evaluate the Safety and Preliminary Efficacy of Bortezomib Combined With Cisplatin in Patients With Recurrent or Metastatic Breast Cancer
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.Clinical breast cancer · 2010Trial
- Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications.Nanomedicine (London, England) · 2024Article
- A Personalized Therapeutics Approach Using anFrontiers in oncology · 2021Article
- A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically.Nanomedicine : nanotechnology, biology, and medicine · 2018Article
- A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.Acta pharmacologica Sinica · 2017Article
- Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells.Scientific reports · 2017Article
- The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.OncoTargets and therapy · 2017Review
- Article
- Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.Biomaterials · 2015Article
- Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer.International journal of nanomedicine · 2015Article
- IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.International journal of oncology · 2014Article
- A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.Cancer cell · 2013Article
- CIP2A is a target of bortezomib in human triple negative breast cancer cells.Breast cancer research : BCR · 2012Article
- Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.Anti-cancer drugs · 2012Article
- Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.Biochemistry research international · 2012Article
- Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells.British journal of cancer · 2011Article
- Article
- A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.Cancer chemotherapy and pharmacology · 2010Article
- Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.Journal of experimental & clinical cancer research : CR · 2010Article
- Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.Cancer research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of bortezomib plus docetaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Forty-eight patients received up to eight 21-day cycles of docetaxel (60-100 mg m(-2) on day 1) plus bortezomib (1.0-1.5 mg m(-2) on days 1, 4, 8, and 11). Pharmacodynamic and pharmacokinetic analyses were performed in a subset of patients. Five patients experienced DLTs: grade 3 bone pain (n=1) and febrile neutropenia (n=4). The MTD was bortezomib 1.5 mg m(-2) plus docetaxel 75 mg m(-2). All 48 patients were assessable for safety and efficacy. The most common adverse events were diarrhoea, nausea, alopecia, asthenia, and vomiting. The most common grade 3/4 toxicities were neutropenia (44%), and febrile neutropenia and diarrhoea (each 19%). Overall patient response rate was 29%. Median time to progression was 5.4 months. In patients with confirmed response, median time to response was 1.3 months and median duration of response was 3.2 months. At the MTD, response rate was 38%. Pharmacokinetic characteristics of bortezomib/docetaxel were comparable with single-agent data. Addition of docetaxel appeared not to affect bortezomib inhibition of 20S proteasome activity. Mean alpha-1 acid glycoprotein concentrations increased from baseline at nearly all time points across different bortezomib dose levels. Bortezomib plus docetaxel is an active combination for anthracycline-pretreated advanced/metastatic breast cancer. The safety profile is manageable and consistent with the side effects of the individual agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.